Tumor responsiveness of squamous cell carcinoma to cisplatin

C. M. Stiernberg, K. Valyi-Nagy, P. E. Hale, F. B. Quinn, B. J. Bailey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The addition of chemotherapy to planned multiple modality treatment of patients with advanced head and neck squamous cell carcinomas may improve survival rates, but individual tumor response is unpredictable. An assay for determining tumor responsiveness to specific chemotherapeutic agents would facilitate treatment selection. This study used the subrenal capsule (SRC) assay to test responsiveness of squamous cell carcinoma to cisplatin. Tumor xenografts obtained from ten patients were implanted beneath the renal capsules of control and treatment mice. Tumor responsiveness was determined by using the paired Student's t-test to compare base-line and post-treatment measurements in the cisplatin-treated mice. Results indicated six of ten tumors were sensitive to cisplatin. In conclusion, tumor sensitivity to cisplatin and other drugs may be predictable with the SRC assay, but to be clinically useful, studies will be necessary to correlate assay results with responses observed in patients.

Original languageEnglish (US)
Pages (from-to)758-762
Number of pages5
JournalLaryngoscope
Volume96
Issue number7
StatePublished - 1986

Fingerprint

Cisplatin
Squamous Cell Carcinoma
Subrenal Capsule Assay
Neoplasms
Therapeutics
Heterografts
Capsules
Survival Rate
Students
Kidney
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Stiernberg, C. M., Valyi-Nagy, K., Hale, P. E., Quinn, F. B., & Bailey, B. J. (1986). Tumor responsiveness of squamous cell carcinoma to cisplatin. Laryngoscope, 96(7), 758-762.

Tumor responsiveness of squamous cell carcinoma to cisplatin. / Stiernberg, C. M.; Valyi-Nagy, K.; Hale, P. E.; Quinn, F. B.; Bailey, B. J.

In: Laryngoscope, Vol. 96, No. 7, 1986, p. 758-762.

Research output: Contribution to journalArticle

Stiernberg, CM, Valyi-Nagy, K, Hale, PE, Quinn, FB & Bailey, BJ 1986, 'Tumor responsiveness of squamous cell carcinoma to cisplatin', Laryngoscope, vol. 96, no. 7, pp. 758-762.
Stiernberg CM, Valyi-Nagy K, Hale PE, Quinn FB, Bailey BJ. Tumor responsiveness of squamous cell carcinoma to cisplatin. Laryngoscope. 1986;96(7):758-762.
Stiernberg, C. M. ; Valyi-Nagy, K. ; Hale, P. E. ; Quinn, F. B. ; Bailey, B. J. / Tumor responsiveness of squamous cell carcinoma to cisplatin. In: Laryngoscope. 1986 ; Vol. 96, No. 7. pp. 758-762.
@article{18e88f9d3b08441a9f85486992cca297,
title = "Tumor responsiveness of squamous cell carcinoma to cisplatin",
abstract = "The addition of chemotherapy to planned multiple modality treatment of patients with advanced head and neck squamous cell carcinomas may improve survival rates, but individual tumor response is unpredictable. An assay for determining tumor responsiveness to specific chemotherapeutic agents would facilitate treatment selection. This study used the subrenal capsule (SRC) assay to test responsiveness of squamous cell carcinoma to cisplatin. Tumor xenografts obtained from ten patients were implanted beneath the renal capsules of control and treatment mice. Tumor responsiveness was determined by using the paired Student's t-test to compare base-line and post-treatment measurements in the cisplatin-treated mice. Results indicated six of ten tumors were sensitive to cisplatin. In conclusion, tumor sensitivity to cisplatin and other drugs may be predictable with the SRC assay, but to be clinically useful, studies will be necessary to correlate assay results with responses observed in patients.",
author = "Stiernberg, {C. M.} and K. Valyi-Nagy and Hale, {P. E.} and Quinn, {F. B.} and Bailey, {B. J.}",
year = "1986",
language = "English (US)",
volume = "96",
pages = "758--762",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Tumor responsiveness of squamous cell carcinoma to cisplatin

AU - Stiernberg, C. M.

AU - Valyi-Nagy, K.

AU - Hale, P. E.

AU - Quinn, F. B.

AU - Bailey, B. J.

PY - 1986

Y1 - 1986

N2 - The addition of chemotherapy to planned multiple modality treatment of patients with advanced head and neck squamous cell carcinomas may improve survival rates, but individual tumor response is unpredictable. An assay for determining tumor responsiveness to specific chemotherapeutic agents would facilitate treatment selection. This study used the subrenal capsule (SRC) assay to test responsiveness of squamous cell carcinoma to cisplatin. Tumor xenografts obtained from ten patients were implanted beneath the renal capsules of control and treatment mice. Tumor responsiveness was determined by using the paired Student's t-test to compare base-line and post-treatment measurements in the cisplatin-treated mice. Results indicated six of ten tumors were sensitive to cisplatin. In conclusion, tumor sensitivity to cisplatin and other drugs may be predictable with the SRC assay, but to be clinically useful, studies will be necessary to correlate assay results with responses observed in patients.

AB - The addition of chemotherapy to planned multiple modality treatment of patients with advanced head and neck squamous cell carcinomas may improve survival rates, but individual tumor response is unpredictable. An assay for determining tumor responsiveness to specific chemotherapeutic agents would facilitate treatment selection. This study used the subrenal capsule (SRC) assay to test responsiveness of squamous cell carcinoma to cisplatin. Tumor xenografts obtained from ten patients were implanted beneath the renal capsules of control and treatment mice. Tumor responsiveness was determined by using the paired Student's t-test to compare base-line and post-treatment measurements in the cisplatin-treated mice. Results indicated six of ten tumors were sensitive to cisplatin. In conclusion, tumor sensitivity to cisplatin and other drugs may be predictable with the SRC assay, but to be clinically useful, studies will be necessary to correlate assay results with responses observed in patients.

UR - http://www.scopus.com/inward/record.url?scp=0022541489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022541489&partnerID=8YFLogxK

M3 - Article

VL - 96

SP - 758

EP - 762

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 7

ER -